Asset Details
Do you wish to reserve the book?
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Do you wish to request the book?
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
2019
Overview
Patients with interstitial lung disease associated with systemic sclerosis were treated with usual care plus placebo or nintedanib. The annual rate of change in forced vital capacity assessed over a 52-week period was −52.4 ml per year with nintedanib and −93.3 ml per year with placebo. There were no differences in other measures of systemic sclerosis.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Diarrhea
/ Diarrhea - chemically induced
/ Enzyme Inhibitors - adverse effects
/ Enzyme Inhibitors - therapeutic use
/ Female
/ Fibrosis
/ Humans
/ Lung Diseases, Interstitial - drug therapy
/ Lung Diseases, Interstitial - etiology
/ Lung Diseases, Interstitial - physiopathology
/ Male
/ Patients
/ Protein-Tyrosine Kinases - antagonists & inhibitors
/ Scleroderma, Systemic - complications
/ Scleroderma, Systemic - drug therapy
/ Skin
